Vertex taps Halozyme and its recently acquired Elektrofi tech in $15M drug delivery deal
Vertex Pharmaceuticals has entered a $15 million upfront deal with Halozyme to license its Hypercon microparticle, high-concentration formulation technology, which was developed by Elektrofi. This technology aims to enable reduced injection volumes for drugs and biologics, supporting at-home administration, particularly for "small volume, patient-delivered next-generation biologics." The agreement includes potential milestone payments and royalties for Halozyme, as Vertex seeks to employ the tech across up to three drug targets within its pipeline.
Sanofi immune drug hopeful posts mixed results in mid-stage tests
Sanofi's experimental bispecific drug, lunsekimig, achieved its primary and secondary goals in Phase 2 trials for moderate-to-severe asthma and chronic rhinitis with nasal polyps, showing benefit in reducing flare-ups and improving lung function. However, the drug failed to meet its main objective in a separate trial for atopic dermatitis. These mixed results come as Sanofi seeks a successor to its top-selling drug Dupixent.
Halozyme Hypercon, Vertex Pharmaceuticals Enter Exclusive Collab & License Agreement
Halozyme Therapeutics Inc. has entered an exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated, granting Vertex rights to Halozyme's Hypercon technology for up to three drug targets. Hypercon's microparticle technology aims to reduce injection volume for drug administration, enabling convenient at-home use. Under the agreement, Halozyme will receive a $15 million upfront payment and potential future milestone payments and royalties.
Halozyme Announces Global Collaboration And License Agreement With Vertex Pharmaceuticals For Hypercon™ Technology
Halozyme Therapeutics announced a global collaboration and license agreement with Vertex Pharmaceuticals for its Hypercon™ technology. The agreement signifies a strategic partnership between the two companies, leveraging Halozyme's drug delivery platform. This collaboration is expected to advance the development and commercialization of new therapies using Hypercon™ technology.
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
Halozyme Therapeutics, Inc. has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals for its Hypercon™ technology. This microparticle technology aims to reduce drug injection volumes, enabling more convenient at-home administration. The agreement includes a $15 million upfront payment to Halozyme, with potential for future milestone payments and royalties on net sales of developed products.
Rheos Capital Works Inc. Buys 1,100,000 Shares of Joby Aviation, Inc. $JOBY
Rheos Capital Works Inc. significantly increased its stake in Joby Aviation, purchasing an additional 1.1 million shares to bring its total holdings to 3.545 million shares, valued at approximately $46.8 million. Despite Joby Aviation beating earnings expectations and strong institutional investment, analysts maintain a cautious "Reduce" rating with an average price target of $13.81, and company insiders have recently sold over 1.3 million shares. This move by Rheos Capital Works makes Joby Aviation their 7th largest holding, amidst continued insider selling and mixed analyst sentiment.
Spero Therapeutics Stock Rises Above 50-Day Average
Shares of Spero Therapeutics (NASDAQ:SPRO) have surpassed their 50-day moving average, reaching $2.61. This rise is considered a bullish signal, but investors are questioning whether it indicates the stock is overbought. The company is developing an oral carbapenem antibiotic for complicated urinary tract infections.
Vertex Pharmaceuticals to Report Q1 2026 Earnings on May 4
Vertex Pharmaceuticals (Nasdaq: VRTX) is scheduled to release its first-quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss the earnings. This report is highly anticipated by investors and analysts for insights into the biotech firm's financial health, product sales, and pipeline development.
Disc Medicine (IRON) Is Up 7.2% After Advancing Bitopertin Phase 3 Despite FDA Efficacy Concerns
Disc Medicine's stock rose 7.2% after it announced the completion of patient enrollment and dosing in its expanded pivotal Phase 3 APOLLO trial for bitopertin, a drug for erythropoietic and X-linked protoporphyria. This development occurs despite a previous FDA Complete Response Letter citing insufficient efficacy in earlier trials, creating a complex risk-reward profile for the company. The market's reaction reflects a renewed interest in the drug's potential, betting on the success of the Phase 3 data expected in late 2026.
Travere Therapeutics (TVTX) seeks approval to add 3M shares to 2018 equity plan
Travere Therapeutics (TVTX) is seeking stockholder approval at its 2026 Annual Meeting to increase the number of shares authorized for its 2018 Equity Incentive Plan by 3 million. This increase is deemed crucial for attracting, retaining, and motivating employees to support the company's growth, including the commercial launch of FILSPARI® (sparsentan) for IgAN and potential approval for FSGS. The proposal emphasizes that equity awards are essential for aligning employee incentives with stockholder interests, especially given the company's significant business expansion and competitive biopharmaceutical labor market.
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. (VRTX) shares fell 1.01% to $434.30 on Monday, marking its second consecutive day of losses. Despite this decline, the stock still outperformed the broader market, as the S&P 500 Index and Dow Jones Industrial Average both saw gains. The article highlights VRTX's performance relative to its competitors on a favorable trading day for the overall market.
Biotech layoff pick back up as 14 companies cut 745 jobs in Q1
In the first quarter of 2026, 14 biotech companies announced layoffs, resulting in 745 job cuts. This number marks an increase from the previous quarter, which saw 476 workers lose their jobs. Companies such as Tessera, Vertex, and Takeda were among those implementing cuts.
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
This article analyzes the Q4 earnings of Myriad Genetics (NASDAQ:MYGN) and compares its performance with other therapeutics stocks. While the therapeutics sector saw strong revenue beats collectively, individual stock performances varied. Myriad Genetics exceeded expectations with flat year-on-year revenue and strong full-year EBITDA guidance, showcasing positive momentum in key testing areas.
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
This article analyzes the Q4 earnings across various therapeutics stocks, spotlighting Myriad Genetics' performance relative to its peers. Myriad Genetics (MYGN) exceeded analyst expectations with flat year-on-year revenue but strong full-year EBITDA guidance, driven by growth in cancer and mental health testing. The piece also reviews the results of Novavax (NVAX), United Therapeutics (UTHR), Vertex Pharmaceuticals (VRTX), and AbbVie (ABBV), highlighting their revenue performance, market reactions, and key business developments.
A Look At Dyne Therapeutics (DYN) Valuation After Strong Recent Share Price Momentum
Dyne Therapeutics (DYN) has seen significant share price momentum, with a 26.8% return over the past month and a 127.5% return over the past year. Despite being a clinical-stage, loss-making company with a market value of $3.1 billion, its Price-to-Book ratio of 3.2x is lower than peers but higher than the broader US biotech industry average. A discounted cash flow model suggests the stock is trading at an 85% discount to its estimated future cash flow value of $126.01, indicating a potentially large valuation gap.
Does New CF Approvals And IgAN Filing Change The Bull Case For Vertex Pharmaceuticals (VRTX)?
Vertex Pharmaceuticals recently received expanded U.S. FDA approvals for its cystic fibrosis therapies and completed a Biologics License Application for povetacicept for immunoglobulin A nephropathy. These developments aim to diversify Vertex's portfolio beyond its core CF business, but the investment narrative still hinges on the success of these new areas while managing long-term risks in the CF market. Despite promising projections of $16.0 billion revenue by 2029 and a fair value suggesting a 25% upside, analysts remain divided on the company's ability to achieve these growth targets given R&D needs and pricing pressures.
Nisa Investment Advisors Reduces Neurocrine Biosciences Stake
Nisa Investment Advisors LLC significantly reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 80.8% in the fourth quarter of 2025, selling 21,945 shares. The institutional investor now owns 5,201 shares worth approximately $738,000. While the specific reasons for this portfolio adjustment were not disclosed, it could indicate a shift in investor sentiment or strategy concerning the biopharmaceutical company's future.
CRISPR Therapeutics AG (CRSP) stock price, news, quote and history
This page provides comprehensive information on CRISPR Therapeutics AG (CRSP), a gene-editing company. It includes real-time stock price data, historical performance, key financial metrics, analyst insights, and comparisons with similar biotechnology firms. The company specializes in gene-based medicines using its CRISPR/Cas9 platform, with lead product CASGEVY for blood disorders and various CAR T-cell therapies in development.
Vertex Pharmaceuticals EVP Sells $439,288 in Stock
Vertex Pharmaceuticals Executive Vice President Joy Liu sold 978 shares of company stock for $439,288.26 on April 1st, 2026. This transaction reduced Liu's ownership by 4.29% to 21,833 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. Insider sales can offer insights into executive sentiment, and investors will monitor this and future activities to gauge the company's outlook.
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $439,288.26 in Stock
Vertex Pharmaceuticals (NASDAQ:VRTX) Executive Vice President Joy Liu sold 978 shares of the company's stock on April 1st for $439,288.26, reducing her holdings by 4.29%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling, analysts maintain a "Moderate Buy" rating for VRTX with an average price target of $554.30.
Insider Sell: Joy Liu Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
Joy Liu, Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals Inc (VRTX), sold 978 shares of the company on April 1, 2026, reducing her holdings to 21,833 shares. This transaction follows a pattern of 42 insider sells against 2 insider buys over the last year for VRTX. Despite the insider selling, Vertex Pharmaceuticals Inc is considered modestly undervalued with a price-to-GF-Value ratio of 0.91, trading at $449.17 per share against a GF Value of $492.31.
CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History
This article provides a comprehensive overview of CRISPR Therapeutics AG (CRSP) stock, including its current price, historical performance, key financial metrics, and recent news. It details the company's focus on gene editing using its CRISPR/Cas9 platform to develop gene-based medicines for various serious human diseases, highlighting its lead product candidate CASGEVY and other pipeline programs. The report also includes analyst insights and comparisons with similar biotechnology companies.
Vertex (VRTX) legal chief sells 978 shares under 10b5-1 plan
Joy Liu, EVP and Chief Legal Officer of Vertex Pharmaceuticals (VRTX), sold 978 shares of common stock at an average price of $449.17 per share on April 1, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan established on November 25, 2025. Following the sale, Liu directly holds 21,833 Vertex shares.
Vertex FDA Label Expansion Lifts CF Coverage to 95%: Is $500 Next?
Vertex Pharmaceuticals (VRTX) recently secured FDA label expansions for its cystic fibrosis (CF) treatments, ALYFTREK and TRIKAFTA, increasing patient eligibility to 95% of U.S. CF patients. The company is also advancing a significant kidney disease pipeline, with its drug povetacicept showing promising Phase 3 interim results. Wall Street analysts maintain a high price target for VRTX, with TIKR's model projecting a mid-case price target of $827.11 by 2030, driven by non-CF revenue growth and pipeline expansion.
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro
The Multiple System Atrophy (MSA) market is projected for significant growth, from USD 44 million in 2025 to USD 1,753 million by 2034, driven by advancements in therapies from companies like Alterity Therapeutics, Ionis Pharmaceuticals, and Biohaven Pharmaceuticals. The US currently holds the largest market share, with Germany leading in EU4 and the UK. The report highlights upcoming therapies and stresses the increasing prevalence and awareness of this rare neurodegenerative disorder as key market drivers.
Biohaven Ltd. (BHVN) stock price, news, quote and history
This article provides a comprehensive overview of Biohaven Ltd. (BHVN), including its current stock price ($9.88, down 0.40%), recent news, and historical performance. The biotech company focuses on developing treatments across immunology, neuroscience, and oncology, with several drug candidates in various clinical trial stages. Key financial metrics, analyst insights, and comparisons to similar companies are also presented.
Aberdeen Group Reduces Stake in Vertex Pharmaceuticals
Aberdeen Group plc, a major institutional investor, decreased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 16.8% during the fourth quarter of 2025. The firm's 13F filing shows it now holds 262,057 shares worth $118.81 million. This reduction suggests a potential shift in investor sentiment regarding the biotech company, which focuses on treatments for serious diseases like cystic fibrosis.
Comparing Apellis Pharmaceuticals With Industry Competitors In Biotechnology Industry
This article compares Apellis Pharmaceuticals (NASDAQ: APLS) with its biotechnology industry peers, analyzing financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. While Apellis shows potential undervaluation based on its P/S ratio, other indicators suggest overvaluation and weaker financial performance, including a high debt-to-equity ratio, compared to its competitors. The analysis aims to provide investors with insights into the company's standing within the competitive biotechnology sector.
Aberdeen Group plc Has $118.81 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Aberdeen Group plc decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 16.8% in the fourth quarter, reducing its holdings to 262,057 shares worth $118.81 million. Despite this, other institutional investors like Vanguard Group Inc., Capital Research Global Investors, and Capital International Investors significantly increased their positions in the pharmaceutical company. Vertex Pharmaceuticals reported Q4 earnings of $5.03 per share, missing estimates slightly, with revenue reaching $3.19 billion.
Takeda Pharmaceuticals to lay off 247 employees in Massachusetts
Takeda Pharmaceuticals, the largest biopharma employer in Massachusetts, will lay off 247 employees in Cambridge starting in July as part of a restructuring plan to cut $1.3 billion in costs. The company cites high taxes, climate mandates, and an unfriendly business environment in Massachusetts as reasons, with an additional 387 job cuts planned in other states. This move is contributing to concerns about the state's ability to retain businesses and talent amid rising costs and regulatory challenges.
[ARS] VERTEX PHARMACEUTICALS INC / MA SEC Filing
This article reports on an ARS SEC filing by VERTEX PHARMACEUTICALS INC / MA (VRTX) on April 2, 2026, at 04:06 PM. The filing is categorized with a low impact and neutral sentiment. It provides key company data such as market cap, float, industry, country, and city, along with recent news and other SEC filings from Vertex Pharmaceuticals.
Onconetix (STU:J4T1) Cyclically Adjusted Price-to-FCF : (As of Apr. 02, 2026)
This article explains the concept of Cyclically Adjusted Price-to-FCF (CAPFCF) as applied to Onconetix (STU:J4T1). It highlights that due to insufficient historical data, GuruFocus cannot calculate the CAPFCF for Onconetix. The article details what CAPFCF is, how it differs from regular Price-to-Free-Cash-Flow, and lists related financial terms.
Jefferies (NYSE: JEF) $1.25M autocallable notes linked to CAT, GS, NOW, VRTX
Jefferies Financial Group Inc. has issued $1.25 million in Senior Autocallable Contingent Coupon Buffered Notes due April 5, 2028, linked to the performance of Caterpillar, Goldman Sachs, ServiceNow, and Vertex Pharmaceuticals. These notes offer quarterly contingent coupons of $66.25 if the worst-performing underlying meets its coupon barrier, with an autocall feature on quarterly observation dates. Investors face principal risk at maturity if the worst-performing underlying falls below its 55% threshold, potentially losing up to 55% of the stated principal.
Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial
Biohaven (BHVN) saw its stock rise by 11.7% after announcing the completion of enrollment for its Phase 2 obesity drug trial of taldefgrobep alfa. This drug is notable for its potential to reduce fat while increasing lean muscle mass, with topline data expected in the second half of 2026. The full enrollment is a positive catalyst for the company, although Biohaven still faces challenges related to its loss-making status and funding needs.
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Shares of Vertex Pharmaceuticals Inc. (VRTX) fell 1.91% to $438.71 on Thursday, breaking a three-day winning streak despite a mixed trading session for the broader market. The S&P 500 Index saw a slight gain, while the Dow Jones Industrial Average experienced a small decline. This performance highlights the stock's outperformance relative to competitors, even on a down day.
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR)
This article provides a detailed overview of Monopar Therapeutics Inc (NASDAQ: MNPR) stock, including its current price, performance, key statistics, and technical and fundamental analysis ratings from ChartMill. It also covers earnings, analyst forecasts, financial highlights, ownership details, and a company profile outlining its biopharmaceutical focus on cancer treatments.
Abivax (WBO:ABVX) Shiller PE Ratio : (As of Apr. 02, 2026)
This article from GuruFocus provides a detailed explanation and historical data for Abivax (WBO:ABVX)'s Shiller PE Ratio as of April 2, 2026. It highlights the calculation methodology for the Shiller PE Ratio, its comparison to the regular PE Ratio, and its application in assessing valuation for cyclical businesses. The article also provides historical data trends, industry comparisons, and related financial terms, noting that some detailed features are exclusive to premium members.
The Opioid Crisis Was an Innovation Failure. Vertex Just Showed a Way to Fix It
The opioid crisis highlights a long-standing issue in pain management, where aggressive treatment risks addiction, and conservative approaches leave patients in pain. Vertex Pharmaceuticals has introduced Journavx, a non-opioid pain medicine that addresses this dilemma by targeting pain signals before they reach the brain, avoiding the reward pathways associated with opioids. This innovation illustrates a new model for drug development focused on validated biology and tight execution, moving away from the costly "shots-on-goal" approach that has historically failed to deliver effective results.
F&V Capital Management LLC Buys Shares of 3,645 Vertex Pharmaceuticals Incorporated $VRTX
F&V Capital Management LLC recently acquired 3,645 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $1.65 million, contributing to institutional investors owning around 90.96% of the stock. Despite this, company insiders have been net sellers, offloading 93,485 shares worth $43.97 million in the last quarter. Wall Street analysts maintain a "Moderate Buy" consensus rating with a target price of $554.30, even though the company recently reported Q4 revenue up 9.5% but an EPS that slightly missed estimates.
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders
Dyne Therapeutics (DYN) recently filed a US$40.81 million shelf registration for an employee stock ownership plan and is focusing on payer engagement and launch preparations for Duchenne and myotonic dystrophy treatments. This move reinforces dilution risk but also highlights their commercialization strategy, aiming to translate clinical data into market access. Investor opinions on Dyne's valuation are divided, given its status as a high-risk, late-stage rare disease platform with no revenue and a notable cash burn.
Allspring Global Investments Holdings LLC Cuts Stock Position in Vertex Pharmaceuticals Incorporated $VRTX
Allspring Global Investments Holdings LLC reduced its stake in Vertex Pharmaceuticals Incorporated by 3.7% in the fourth quarter, selling 4,653 shares and holding 122,210 shares worth $55.26 million. Other institutional investors also adjusted their positions in VRTX, with notable increases from Chesapeake Asset Management LLC and Y.D. More Investments Ltd. Insider selling also occurred, with CMO Carmen Bozic and EVP Ourania Tatsis reducing their holdings.
Vertex Pharmaceuticals Inc - FDA expands indication for trikafta in cf patients ages 2 and older
Vertex Pharmaceuticals Inc. has announced that the U.S. FDA has expanded the indication for its drug Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for cystic fibrosis patients aged 2 years and older. This approval broadens the access to the medication for younger patients with specific CFTR gene mutations. The company also announced FDA approval for expanded use of ALYFTREK.
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Banque Pictet & Cie SA
Banque Pictet & Cie SA significantly increased its stake in Vertex Pharmaceuticals (VRTX) by 174.6% in Q4, acquiring an additional 15,470 shares. This move brings their total holdings to 24,328 shares, valued at approximately $11.03 million. Despite substantial insider selling from executives, analysts largely maintain a "Moderate Buy" rating for VRTX, with an average target price of $554.30.
Vertex Pharmaceuticals Says US FDA Approves Label Expansion for Alyftrek, Trikafta
Vertex Pharmaceuticals announced that the US FDA has approved label expansions for its cystic fibrosis medications, Alyftrek and Trikafta. Alyftrek is now approved for pediatric patients aged one year and older, while Trikafta's label is expanded to include patients as young as six months. These approvals broaden the treatment options for younger cystic fibrosis patients.
Vertex Pharmaceuticals (NASDAQ: VRTX) reports 978-share Rule 144 resale and insider sales
Vertex Pharmaceuticals (VRTX) has reported a Rule 144 notice for the planned resale of 978 shares of common stock stemming from a Restricted Stock Vesting event on February 17, 2025. The filing also details several insider sales by Joy Liu, who sold a total of 12,409 shares between January 5 and March 2, 2026, generating gross proceeds of over $6 million. These transactions are considered routine administrative disclosures and do not indicate changes to the company's capital structure.
Jefferies (JEF) issues autocallable notes with $66.25 contingent coupons
Jefferies Financial Group Inc. is offering Senior Autocallable Contingent Coupon Buffered Notes due April 5, 2028, linked to the worst-performing stock among Caterpillar, Goldman Sachs, ServiceNow, and Vertex. These notes have a stated principal amount of $1,000 and offer quarterly contingent coupons of $66.25 if the worst-performing underlying meets its coupon barrier. The notes are also autocallable, but payments are unsecured and subject to Jefferies' credit risk, with investors potentially losing up to 55% of their principal if underlying thresholds are not met.
Vertex wins FDA nod to expand cystic fibrosis drug indications By Investing.com
Vertex Pharmaceuticals announced that the FDA has expanded the indications for its cystic fibrosis drugs, ALYFTREK and TRIKAFTA, to include more patients. This expansion covers approximately 800 additional people in the U.S. and means about 95% of cystic fibrosis patients in the U.S. are now eligible for CFTR modulator treatment. Despite recent downward revisions in earnings estimates by some analysts, Vertex maintains a strong market position and profitability.
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States
Vertex Pharmaceuticals announced that the U.S. FDA has approved label extensions for ALYFTREK® and TRIKAFTA®, significantly broadening their eligibility for treating cystic fibrosis (CF). This expansion now means approximately 95% of people with CF in the U.S. are eligible for a CFTR modulator, adding about 800 more patients who can receive treatment for the underlying cause of their disease. The approvals are based on extensive clinical and in vitro data, emphasizing Vertex's long-term commitment to CF research.
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
Vertex Pharmaceuticals announced that the U.S. FDA has approved expanded use for its cystic fibrosis (CF) drugs, ALYFTREK and TRIKAFTA. This approval will make these treatments available to approximately 800 more people with CF in the U.S., increasing the total eligibility to about 95% of the CF population. The label extensions cover all variants producing CFTR protein, reinforcing the drugs' broad impact regardless of variant location.
FDA move makes 800 more US patients eligible for Vertex CF drugs
Vertex Pharmaceuticals (VRTX) announced FDA approval for expanded use of its cystic fibrosis drugs, ALYFTREK and TRIKAFTA. This label extension makes these treatments available to approximately 800 additional U.S. patients, covering about 95% of all people with CF in the country. The expansion includes any CFTR gene variant that results in the production of the CFTR protein, underscoring the drugs' broad impact regardless of the variant's location.
